Predicted protein targets (top 9)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SMO | Q99835 | 8/20 | 0.36 |
| ▸ | GPR119 | Q8TDV5 | 2/20 | 0.34 |
| ▸ | BTK | Q06187 | 3/20 | 0.33 |
| ▸ | TIPARP | Q7Z3E1 | 4/20 | 0.33 |
| ▸ | FPR1 | P21462 | 1/20 | 0.33 |
| ▸ | FPR2 | P25090 | 1/20 | 0.33 |
| ▸ | NR1H2 | P55055 | 1/20 | 0.33 |
| ▸ | NR1H3 | Q13133 | 1/20 | 0.33 |
| ▸ | ROCK2 | O75116 | 1/20 | 0.32 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL2599233 | 1.00 | SMO (0.36) | SMOGPR119BTKTIPARPFPR1 | |
| SCHEMBL2598414 | 0.95 | BTK (0.39) | SMOGPR119BTK | |
| SCHEMBL15047759 | 0.94 | BTK (0.37) | SMOGPR119BTK | |
| SCHEMBL2597119 | 0.94 | SMO (0.38) | SMOGPR119BTKTIPARPFPR1 | |
| SCHEMBL2597120 | 0.94 | SMO (0.38) | SMOGPR119BTKTIPARPFPR1 | |
| Hydrochloric Acid SCHEMBL15022872 | 0.93 | BTK (0.36) | SMOGPR119BTK | |
| Hydrochloric Acid SCHEMBL15022871 | 0.93 | BTK (0.36) | SMOGPR119BTK | |
| SCHEMBL15022755 | 0.89 | GPR119 (0.34) | SMOGPR119BTKTIPARPFPR2 | |
| SCHEMBL12185787 | 0.89 | GPR119 (0.34) | SMOGPR119BTKTIPARPFPR2 | |
| SCHEMBL15023415 | 0.89 | RIPK1 (0.38) | GPR119BTKTIPARPNR1H2NR1H3 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8754226-B2 | Piperidinyl-substituted lactams as GPR119 modulators | ARRAY BIOPHARMA INC. (US) | 2014-06-17 | — | — | US | disclosed |
| US-8754226-B2 | Piperidinyl-substituted lactams as GPR119 modulators | ARRAY BIOPHARMA INC. (US) | 2014-06-17 | — | — | US | disclosed |
| US-20130158009-A1 | PIPERIDINYL-SUBSTITUTED LACTAMS AS GPR119 MODULATORS | ARRAY BIOPHARMA, INC. | 2013-06-20 | — | — | US | disclosed |
| US-20130158009-A1 | PIPERIDINYL-SUBSTITUTED LACTAMS AS GPR119 MODULATORS | ARRAY BIOPHARMA, INC. | 2013-06-20 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20130158009-A1 | PIPERIDINYL-SUBSTITUTED LACTAMS AS GPR119 MODULATORS | GPR119, GPR139, GPR39 | SMO 1484/4885GPR119 1/4885BTK 3330/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.